Skip to main content
logo
Latigo Biotherapeutics, Inc. (LTGO)
NASDAQ: LTGO · Real-Time Price · USD
14.76
+0.76 (5.43%)
Oct 15, 2026, 4:00 PM EDT - Market closed

Latigo Biotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-111.14-109.17-61.18
Depreciation & Amortization
0.220.250.24
Stock-Based Compensation
7.696.732.77
Other Operating Activities
1.342.120.33
Change in Accounts Payable
-1.96-1.965.75
Change in Other Net Operating Assets
0.394.481.14
Operating Cash Flow
-103.19-97.56-50.96
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-0.11-0.14-0.07
Investing Cash Flow
-0.11-0.14-0.07

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Issuance of Common Stock
0.350.120.61
Financing Cash Flow
84.01149.50.61

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
-19.2951.8-50.42

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-103.3-97.69-51.03
Free Cash Flow Growth
---
Free Cash Flow Per Share
-108.51-115.65-75.14
Levered Free Cash Flow
--59.47-
Unlevered Free Cash Flow
--59.47-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
-1.582.526.89
SEC Filings: 10-K · 10-Q